Feed aggregator

Bluebird Bio’s Sickle Cell Gene Therapy Working for French Boy

Bioethics News - Wed, 06/17/2015 - 12:25

(Medical Daily) – A pioneering gene therapy for sickle cell disease is working well so far for a 13-year-old French boy with the hereditary blood disorder, researchers said on Saturday, in a boost for the technology to fix faulty genes. He is the first patient with severe sickle cell disease (SCD) to be treated with Bluebird Bio’s LentiGlobin BB305 product, which the U.S. biotech company believes could cure the disorder.